1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,059 | 0,100 | 23.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.02. | hVIVO PLC - Issue of Equity and Total Voting Rights | - | RNS | ||
| 29.01. | hVIVO PLC - Trading Update | - | RNS | ||
| 27.01. | hVIVO PLC - Notice of Trading Update | - | RNS | ||
| 18.12.25 | hVIVO PLC - Appointment of Non-Executive Director | - | RNS | ||
| 15.12.25 | hVIVO PLC - CEO & CFO Share Purchase | - | RNS | ||
| 12.12.25 | Broker tips: Hvivo, Whitbread, IHG | 3 | Sharecast | ||
| 12.12.25 | Shore Capital hails improved US biotech funding environment for hVIVO | 1 | Sharecast | ||
| HVIVO Aktie jetzt für 0€ handeln | |||||
| 27.11.25 | Hvivo client acquired by MSD in $9.2bn deal | 8 | Sharecast | ||
| 27.11.25 | hVIVO PLC - MSD to acquire Cidara | 24 | RNS | ||
| 20.11.25 | hVIVO PLC - >£5 million CRS contracts signed | - | RNS | ||
| 11.11.25 | hVIVO develops three new human challenge models for viral testing | 3 | Investing.com | ||
| 11.11.25 | hVIVO meldet erfolgreiche Entwicklung von drei neuen humanen Challenge-Modellen | 1 | Investing.com Deutsch | ||
| 11.11.25 | hVIVO PLC - Positive data from novel human challenge models | - | RNS | ||
| 03.11.25 | hVIVO PLC - Presentation at Jefferies Healthcare Conference | - | RNS |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 0,247 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide May Reduce Leptomeningeal Metastases Healthcare Costs by 40% | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| JD HEALTH INTERNATIONAL | 5,450 | +2,83 % | EZZ flexes China growth strategy with JD Health deal | ||
| LIFEWARD | 6,900 | 0,00 % | Lifeward Ltd.: Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results | Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval- Lifeward gains new... ► Artikel lesen | |
| EKSO BIONICS | 10,640 | 0,00 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| IMUNON | 2,280 | -1,72 % | Imunon, Inc.: IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update | R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced... ► Artikel lesen | |
| ROCKWELL MEDICAL | 0,875 | -0,40 % | Why Is Rockwell Medical Gaining Tuesday? | ||
| VIRIDIAN THERAPEUTICS | 23,340 | -0,26 % | Viridian Therapeutics stellt auf TD Cowen Konferenz Strategie für TED-Behandlung vor | ||
| SINTX TECHNOLOGIES | 2,550 | +2,41 % | SINTX Technologies, Inc.: SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution | Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX... ► Artikel lesen | |
| AETHLON MEDICAL | 2,170 | +0,46 % | AETHLON MEDICAL INC - 8-K, Current Report | ||
| NEURONETICS | 1,388 | +11,04 % | Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37%... ► Artikel lesen | |
| SAVARIA | 16,200 | +1,89 % | Savaria Corporation declares CAD 0.0467 dividend | ||
| STAGEZERO LIFE SCIENCES | 0,028 | -100,00 % | StageZero Life Sciences Ltd.: StageZero Announces Partial Revocation of Failure to File Cease Trade Order and Proposed Financing | ||
| ARCH THERAPEUTICS | - | - | Arch Therapeutics, Inc. - 15-12G, Securities registration termination | ||
| IMAC HOLDINGS | 0,192 | -4,00 % | IMAC Holdings, Inc. - 8-K, Current Report |
HVIVO PLC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,076 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HVIVO PLC finden Sie auf Wallstreet Online.